May 15, 2009. On behalf of the National Research Center for Women & Families, I am writing to express our strong support for S. 934, the “Child Nutrition Promotion and School Lunch Protection Act of 2009.”
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Testimony Before DC Health Committee on HPV
April 9, 2009. Like all of you, I am interested in the health and safety of D.C.’s citizens, and like many of you I was, until recently, strongly in favor of mandating the HPV vaccine for girls. Who among us wouldn’t gladly immunize our daughters to protect them from cervical cancer?
Read More »Statement of NCHR At the April 8, 2009 FDA Psychopharmacologic Drugs Advisory Committee Meeting Regarding Seroquel XR
April 8, 2009. We testified arguing that Seroquel, an Antipsychotic medication, should be kept off the market as it has not been conclusively proven that it does not increase the risk of diabetes or tardive dyskinesia.
Read More »NCHR Testimony on Seroquel XR
April 8, 2009. The benefits are statistically significant in most, but not all the studies provided to the FDA. But, let’s be clear here: the patients on placebo are improving greatly in these studies – almost as much as those taking Seroquel.
Read More »Comments to the Consumer Product Safety Commission on “Notice of Availability of Draft Guidance Regarding Which Children’s Products are Subject to the Requirements of CPSIA Section 108”
March 25, 2009. Our groups representing patient, consumer, science and public health interests submit the following comments regarding the draft approach prepared by CPSC staff for determining which products constitute a children’s toy or child care article and are subject to section 108 of the CPSIA.
Read More »